Lonza Lifts Margin Guidance to 34% as Pure-Play CDMO Transformation Completes, Unveils New ADC Capacity Bets
Half-year results call, July 22, 2026
Lonza used its half-year 2026 results call to deliver what CEO Wolfgang Wienand called proof that the company's post-2024 restructuring is now paying off in hard numbers. The Swiss CDMO reported first-half sales of CHF 3.4 billion, up 16% at constant exchange rates, entirely organic this time, in contrast to last year's growth which was flattered by the Vacaville acquisition. Core EBITDA reached CHF 1.2 billion at a 34.8% margin, up 4.4 percentage points year-on-year, prompting management to raise full-year core EBITDA margin guidance to a range of 33% to 34%, from a prior floor of "above 32%." Sales growth guidance was reconfirmed at 11% to 12% CER, a level CFO Philippe Deecke said reflects a strong first half against a "much stronger prior year base" in the second half, particularly in Advanced Synthesis.
Free cash flow improved to CHF 426 million from CHF 116 million a year earlier, helped by CapEx falling to 15.7% of sales from 21.2%. Return on invested capital rose almost 3 points to 13.2% annualized, which Deecke pegged at "probably now close to 2x WACC or so," with further upside expected as margins keep expanding.
CHI Divestment Closes the Pure-Play CDMO Chapter
The most structurally significant item was confirmation that Lonza's transformation into a pure-play contract development and manufacturing organization is essentially complete. The company signed an agreement earlier in the first half to divest its Capsules & Health Ingredients business to Lone Star for an enterprise value of CHF 2.3 billion, with closing expected before year-end. Combined with three prior divestments, this marks, in Wienand's words, a transformation executed "within less than 15 months after announcing our new strategy in late 2024." Going forward, Lonza's reporting is built entirely around three platforms: Integrated Biologics, Advanced Synthesis and Specialized Modalities, with capital allocation now governed by strict return hurdles, an IRR of at least 15% and peak ROIC of at least 30% for any organic or inorganic growth spend.
New ADC Investments in Visp and Stein
Lonza announced two new bioconjugate-related capital projects alongside the results: an expansion of highly potent payload-linker manufacturing in Visp, with ramp-up scheduled for 2029, and a second commercial-scale aseptic ADC fill-finish line in Stein, set to begin ramping in 2030. The Stein project already has what Wienand described as "a major pharmaceutical company as an anchor customer and strategic partner," and both projects are expected to reach peak sales by the mid-2030s. Separately, management disclosed that the existing large-scale Stein fill-finish facility, originally biologics-only, will be broadened to also handle high-value small-molecule drug products, a scope change that pushes the facility's operational start to 2028 but requires only a small incremental capital outlay. Through 2030, Lonza plans to invest more than CHF 7 billion in organic CapEx, the majority of it directed at future growth capacity.
Platform Performance: Advanced Synthesis Surges, Specialized Modalities Rebounds
All three business platforms posted double-digit CER growth in the first half. Advanced Synthesis grew 27.7% to CHF 834 million in sales with a core EBITDA margin of 48.1%, up 6.8 points, driven by small molecules and especially bioconjugates against a soft 2025 comparison base. Deecke was explicit that this margin level will not hold: "There will be a lower margin in the second half... we are happy with margins around 40%, starting with the 48%." Specialized Modalities, which struggled through 2025 on asset adaptation issues in Microbial and operational problems in Cell & Gene, snapped back with 22.6% CER growth and a core EBITDA margin of 28%, up 10.7 points, moving the platform closer to group-average profitability. Integrated Biologics, the largest platform at CHF 1.87 billion in sales, grew a more modest 10% with margin flat at 36%, as ramp-up dilution from the new Visp mammalian asset offset project maturation elsewhere.
On Cell & Gene specifically, Deecke clarified that the operational issues that hit the business last year, which included an FDA Form 483 at Portsmouth, have been resolved but were unrelated to the regulatory observation itself: "I would not want you to make a link between the 483 observations and our operational challenges in the sites." Production has resumed and is expected to contribute to second-half growth.
Demand Environment: No Sign of Outsourcing Pullback
Addressing investor concerns about macro-driven order delays, Wienand said pharma capital spending patterns remain intact, with pharma CapEx-to-sales ratios holding around 5% between 2015 and 2030 based on the company's historical and forward analysis, though increasingly weighted toward U.S. capacity given "recent geopolitical developments." He noted directly that in his regular conversations with key pharma customers, "I have not seen any evidence of a fundamental shift in how they view their strategic partnerships with Lonza or outsourcing more generally." Demand for mammalian capacity continues to outpace supply, he said, with contracting activity remaining elevated at the company's Portsmouth and Vacaville sites specifically because of the regionalization trend.
On phasing, management pushed back against the notion that a step-down in second-half growth signals weakening momentum into 2027. Wienand described the business as inherently lumpy, "not a cookie factory," and pointed to Lonza's long-term algorithm of low-teens average annual CER growth with expanding margins as the correct lens for investors, rather than quarter-to-quarter extrapolation.
Vacaville and Visp: The Next Growth Legs
Vacaville, acquired from Roche, is undergoing a planned second-half shutdown to complete CDMO-readiness upgrades, with full-year site sales expected to be roughly flat versus 2025 at around CHF 0.6 billion. Management reiterated that five contracts already signed as of the January 2026 reporting are expected to offset the gradual decline in Roche-related volumes through 2028, with the site becoming a genuine growth contributor after that and reaching full utilization in the early 2030s. Lonza also disclosed that Vacaville was part of a newly extended strategic collaboration with an unnamed leading U.S. biopharma company covering a broad range of clinical and commercial biologics, an agreement management characterized as demonstrating the differentiated pull of combining multiple manufacturing sites under a single partnership. Meanwhile, the large-scale mammalian asset in Visp has begun its multiyear ramp, which Wienand said is dilutive to margin during ramp-up but will become "an important source of future growth" for the biologics platform.
Management confirmed it will host a Capital Markets Day in October at the Vacaville site, where it plans to provide a deeper look at the Integrated Biologics growth opportunity and its broader value-creation framework.